Brief: Maat Pharma Announces First Patient Dosed In Phase 3 'Ares' Trial

Maat Pharma SA

28/03/2022 17:12

March 28 (Reuters) - Maat Pharma SA  MAAT.PA :
    * ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 'ARES' TRIAL
EVALUATING
MAAT013 IN PATIENTS WITH ACUTE GRAFT-VERSUS-HOST-DISEASE
    * PIVOTAL PHASE 3 CLINICAL TRIAL INVESTIGATES EFFICACY OF
LEAD
MICROBIOME ECOSYSTEM THERAPY MAAT013 AS THIRD-LINE TREATMENT IN
PATIENTS WITH STEROID-RESISTANT GASTROINTESTINAL ACUTE
GRAFT-VERSUS-HOST DISEASE (SR GI-AGVHD)
    * ARES IS FIRST PHASE 3 TRIAL GLOBALLY FOR A
MICROBIOME-BASED
THERAPY IN HAEMATO-ONCOLOGY

Source text for Eikon:  ID:nBw9bz8sNa 
Further company coverage:  MAAT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))